<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="inhibit">
            <roleset id="inhibit.01" name="" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="the entity being inhibited by agent to get binding&#x0A;" />
                    <role n="2" descr="the action or property being inhibited&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>10mM EDTA may have totally inhibited Binding that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadW can inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>GadX activates expression of gadA and gadBC at any pH, while GadX-dependent activation has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>Here, we have found that the downregulation of phosphorylated Stat4, Stat5 and Stat6 has been inhibited by the proteasome inhibitors MG132 and lactacystin, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>Intriguingly, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, have selectively inhibited late events of clathrin-coated vesicle formation involving membrane fission, intersectin SH3A was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>Intriguingly, while the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, have selectively inhibited late events of clathrin-coated vesicle formation involving membrane fission, intersectin SH3A was unique in its ability to block earlier stages (Simpson et al., 1999).</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>Natural killer (NK) cells express cell-surface receptors of the immunoglobulin and C-type lectin superfamilies that recognized major histocompatibility complex (MHC) class I peptides and inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>Nitric oxide (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>PDE4C is one of four mammalian genes that encode multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms that were inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>The N-terminal SH3 domain (SH3A), unlike other SH3 domains from intersectin or various endocytic proteins, is able to specifically inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>The N-terminal SH3 domain (SH3A), unlike other SH3 domains from intersectin or various endocytic proteins, specifically inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml chloramphenicol for inhibiting protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>The phosphatases function and localization will be inhibited if the phosphatase associates with another protein.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and protein extracts from the transfected COS cells inhibit both the C alpha and C beta isoforms of the PKA catalytic subunit with equal efficacy.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>intermediate events leading to the formation of clathrin-coated pits are inhibited by The N-terminal SH3 domain (SH3A) which is unlike other SH3 domains from intersectin or various endocytic proteins.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="EGRAM" no="15">
                    <text>late events of clathrin-coated vesicle formation were inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="16">
                    <text>late events of clathrin-coated vesicle formation will be inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>rolipram inhibits multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms encoded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>Natural killer (NK) cells express cell-surface receptors of the immunoglobulin and C-type lectin superfamilies that recognize major histocompatibility complex (MHC) class I peptides and inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>Binding has been inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>Binding were inhibited by 10mM EDTA (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>For example, P may associate with This synthetic peptide and thereby be inhibited in its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>For example, P may associate with This synthetic peptide and thereby be inhibited in its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>For example, P may have associated with This synthetic peptide and thereby has been inhibited in its binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>For example, glnAp2 promoter associated with the CRP-cAMP complex may have been inhibited in the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>For example, the phosphatase associated with another protein was inhibited in The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 are inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 are inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-leukemia cells wil also be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is concentration dependent and saturable and may be totally inhibited with by coexpression of MAD-3, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 were inhibited by by coexpression of MAD-3 (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>Functional activation of an HIV reporter plasmid by p49/p65 were inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>GadW (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>GadW (NO) inhibiting GadX-dependent activation activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>GadW is able to totally inhibit GadX-dependent activation that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by by coexpression of MAD-3.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>GadX activates expression of gadA and gadBC at any pH, while by coexpression of MAD-3 has inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>GadX activates expression of gadA and gadBC at any pH, while chloramphenicol may have inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>GadX activates expression of gadA and gadBC at any pH, while coexpression of MAD-3 will have inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>GadX activates expression of gadA and gadBC at any pH, while coexpression of MAD-3 will inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>GadX activates expression of gadA and gadBC at any pH, while platelet function is inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>GadX activates expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacystin is observed to inhibit the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>GadX activates expression of gadA and gadBC at any pH, while protein synthesis is inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the CRP-cAMP complex inhibits the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>GadX activates expression of gadA and gadBC at any pH, while the CRP-cAMP complex is able to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>GadX-dependent activation is inhibited by GadW (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>GadX-dependent activation will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>Here, we have found that Binding was inhibited by the 10mM EDTA, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>Here, we have found that Binding was inhibited by the 10mM EDTA, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by the by coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>Here, we have found that Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by the coexpression of MAD-3, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>Here, we have found that GadX-dependent activation is observed to be inhibited by the GadW, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>Here, we have found that GadX-dependent activation was inhibited by the GadW, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>Here, we have found that GadX-dependent activation will be inhibited by the GadW, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>Here, we have found that NK-cell-mediated cytotoxicity is observed to be inhibited by the cell-surface receptors of the immunoglobulin and C-type lectin superfamilies, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>Here, we have found that late events of clathrin-coated vesicle formation is observed to be inhibited by the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>Here, we have found that platelet function will be inhibited by the Nitric oxide, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>Here, we have found that the glnAp2 promoter activity will be inhibited by the the CRP-cAMP complex, while the downreglation of phosphorylated Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Binding is observed to be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent activation is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that by coexpression of MAD-3 inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that by coexpression of MAD-3 will inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell-surface receptors of the immunoglobulin and C-type lectin superfamilies inhibited NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicle formation has been inhibited by the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that proteasome inhibitors MG132 and lactacystin inhibited the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>NK-cell-mediated cytotoxicity in transiently transfected Jurkat T-leukemia cells has also been inhibited by cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>Nitric oxide can totally inhibit platelet function that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>Nitric oxide is able to totally inhibit platelet function that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then Functional activation of an HIV reporter plasmid by p49/p65 were inhibited by 50 mg/ml coexpression of MAD-3.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-cell-mediated cytotoxicity were inhibited by 50 mg/ml cell-surface receptors of the immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicle formation has been inhibited by 50 mg/ml the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then late events of clathrin-coated vesicle formation were about to be inhibited by 50 mg/ml the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml GadW for inhibiting GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml Nitric oxide to inhibit platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml cell-surface receptors of the immunoglobulin and C-type lectin superfamilies to inhibit NK-cell-mediated cytotoxicity.</text>
                    <arg n="0">cell-surface receptors of the immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml proteasome inhibitors MG132 and lactacystin for inhibiting the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>The half-life of the AGT proteins was determined by growing cells at 37 C in LB broth supplemented with 50 mg/ml ampicillin, 50 mg/ml kanamycin and 0.2 mM IPTG until the A600 reached 0.3 and then treating them with 50 mg/ml the CRP-cAMP complex to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>This synthetic peptide inhibited P strongly, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>This synthetic peptide inhibits P strongly, by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase has been produced by he human PKI cDNA, and the CRP-cAMP complex may have inhibited glnAp2 promoter with equal efficacy.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and CRP-cAMP inhibit sigma (54)-dependent glnAp2 with equal efficacy.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and glnAp2 promoter are inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human PKI cDNA, and sigma (54)-dependent glnAp2 are able to be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase was produced by he human PKI cDNA, and CRP-cAMP inhibited sigma (54)-dependent glnAp2 with equal efficacy.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>another protein binding to the phosphatase is observed to inhibit The phosphatases function and localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">The phosphatases function and localization</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>another protein bound to the phosphatase and inhibited its function or localization.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                    <arg n="2">its function or localization</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>another protein inhibited the phosphatase strongly, by 21-fold.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">the phosphatase</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>by coexpression of MAD-3 (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>by coexpression of MAD-3 (NO) that has inhibited Functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>by coexpression of MAD-3 is totally inhibiting Functional activation of an HIV reporter plasmid by p49/p65 that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">by coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>chloramphenicol (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>chloramphenicol (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>chloramphenicol is totally inhibiting protein synthesis that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>coexpression of MAD-3 (NO) activated the soluble isoform of guanylate cyclase in platelets and has inhibited Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>coexpression of MAD-3 (NO) activated the soluble isoform of guanylate cyclase in platelets and was observed to inhibit Functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">coexpression of MAD-3</arg>
                    <arg n="2">Functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>late events of clathrin-coated vesicle formation is concentration dependent and saturable and has been totally inhibited with the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>platelet function are observed to be inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>platelet function is concentration dependent and saturable and may be totally inhibited with Nitric oxide, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>platelet function were inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>platelet function were inhibited by Nitric oxide.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>proteasome inhibitors MG132 and lactacystin (NO) activates the soluble isoform of guanylate cyclase in platelets and inhibits the downregulation of phosphorylated Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>protein extracts from the transfected COS cells inhibits both the C alpha and C beta isoforms of the PKA catalytic subunit strongly, by 21-fold.</text>
                    <arg n="0">protein extracts from the transfected COS cells</arg>
                    <arg n="1">both the C alpha and C beta isoforms of the PKA catalytic subunit</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>protein synthesis are inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>protein synthesis is inhibited by chloramphenicol (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>protein synthesis is observed to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>the 10mM EDTA may have inhibited Binding.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">Binding</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>the CRP-cAMP complex (NO) that has inhibited the glnAp2 promoter activity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>the Nitric oxide may have inhibited platelet function.</text>
                    <arg n="0">Nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I (NO) activated the soluble isoform of guanylate cyclase in platelets and inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I is able to totally inhibit late events of clathrin-coated vesicle formation that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>the chloramphenicol inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 are observed to be inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is concentration dependent and saturable and is able to be totally inhibited with proteasome inhibitors MG132 and lactacystin, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 is concentration dependent and saturable and is observed to be totally inhibited with proteasome inhibitors MG132 and lactacystin, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>the downregulation of phosphorylated Stat4, Stat5 and Stat6 were inhibited by proteasome inhibitors MG132 and lactacystin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacystin</arg>
                    <arg n="2">the downregulation of phosphorylated Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>the glnAp2 promoter activity is observed to be inhibited by the CRP-cAMP complex (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>the glnAp2 promoter activity would be inhibited if glnAp2 promoter associated with the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="1">glnAp2 promoter</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>the the CRP-cAMP complex can inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>the the CRP-cAMP complex inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I have the ability to inhibit late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>the the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I may have inhibited late events of clathrin-coated vesicle formation.</text>
                    <arg n="0">the SH3C and SH3E domains of intersectin, as well as the SH3 domains from the endocytic proteins endophilin I, amphiphysin II and syndaphin I</arg>
                    <arg n="2">late events of clathrin-coated vesicle formation</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>Dam methylation can totally inhibit binding of Lrp/PapI that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>GadX activates expression of gadA and gadBC at any pH, while Dam methylation will have inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>GadX activates expression of gadA and gadBC at any pH, while The N-terminal SH3 domain inhibits intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>GadX activates expression of gadA and gadBC at any pH, while The N-terminal SH3 domain inhibits intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>GadX activates expression of gadA and gadBC at any pH, while The N-terminal SH3 domain is able to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Dam methylation has inhibited binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Dam methylation is observed to inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain has inhibited intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain will inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that The N-terminal SH3 domain will inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding of Lrp/PapI has been inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>The N-terminal SH3 domain is totally inhibiting intermediate events leading to the formation of clathrin-coated pits that is concentration dependent and saturable, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>Transient overexpression in COS cells verified that a heat-stable inhibitor of protein kinase is produced by he human multiple PDE4 cyclic AMP-specific phosphodiesterase isoformsKI cDNA, and P are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>binding of Lrp/PapI has been inhibited by Dam methylation.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>binding of Lrp/PapI is concentration dependent and saturable and is observed to be totally inhibited with Dam methylation, suggesting that divalent cations were required for interaction of IN1B with Vero cells.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>binding of Lrp/PapI is observed to be inhibited by Dam methylation (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>intermediate events leading to the formation of clathrin-coated pits can be inhibited by The N-terminal SH3 domain (NO) which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>rolipram can inhibit multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms strongly, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclic AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>the Dam methylation can inhibit binding of Lrp/PapI.</text>
                    <arg n="0">Dam methylation</arg>
                    <arg n="2">binding of Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>the The N-terminal SH3 domain can inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>the The N-terminal SH3 domain have the ability to inhibit intermediate events leading to the formation of clathrin-coated pits.</text>
                    <arg n="0">The N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events leading to the formation of clathrin-coated pits</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
